DSIP (Delta Sleep-inducing Peptide) lab tests

Seven checks before you trust a DSIP (Delta Sleep-inducing Peptide) certificate

The same seven questions decide whether a certificate of analysis means anything, whichever compound it describes. Six are about the document; the seventh is about what no document can tell you.

1. An independent, batch-matched COA. The certificate must name the batch or lot in your hands, and must come from a laboratory the vendor neither owns nor pays. A specimen certificate from an earlier lot proves nothing about the vial you were sent.
2. HPLC purity, read against a known band. A purity figure is only informative against the distribution for that compound. "Above 98%" is not a claim — the useful question is whether the result sits inside the range the rest of the market reports. How to read HPLC and mass-spec results.
3. Mass-spectrometry identity. HPLC says how much of the sample is one thing; it does not say which thing. Only a mass-spec result establishes identity, and it is the only check that separates compounds a few daltons apart. Contamination is not hypothetical: research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight, enough to produce false-positive results in immunology assays (Clinical and Vaccine Immunology, 2008 — a study of HIV vaccine peptide libraries rather than of any compound on this site).
4. Net content, measured rather than assumed. Purity and quantity are different questions: a vial can be 99.7% pure and still contain two thirds of the labelled mass. Why 10 mg isn't 10 mg.
5. Endotoxin (LAL) on the batch. An absent endotoxin line means the batch was not tested — not that it passed. Endotoxin testing and LAL interpretation.
6. Who ran the test, and what they left off. A laboratory with a record on this compound, named on the certificate, with a verification route back to it. Testing laboratories we track · Red flags in a certificate of analysis.
7. What no test on the vial can establish. A perfect certificate confirms that a vendor sold the correct molecule at the stated quantity. It says nothing about efficacy, dosing, or long-term safety.

Want a vial tested yourself? How to send a peptide for independent HPLC testing.

What DSIP testing has to rule out: a nine-residue overlap

DSIP is an endogenous nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), CAS 62568-57-4 (PubChem CID 68816), C₃₅H₄₈N₁₀O₁₅, molecular weight 848.8 g/mol. Nine residues, all of them common amino acids, give it a composition that overlaps other small neuropeptides. HPLC reports the proportion of a sample that is a single species without identifying which species, so a 99% purity figure is entirely compatible with a different small neuropeptide. Mass spectrometry showing a mass near 848.8 Da is not one check among several for this compound; it is the whole test, and a certificate reporting only HPLC purity does not establish that the vial contains DSIP at all.

The naming trap is the research side of the same problem. In FDA compounding documents the compound appears as emideltide, not DSIP, so searching the regulatory record for "DSIP" returns nothing. An empty result under the name on the vial is the wrong search term, not an absence of regulatory history.

• A batch-matched mass spectrum near 848.8 Da, tied to the lot in hand rather than a specimen certificate from an earlier batch.
• The sequence (WAGGDASGE) and formula (C₃₅H₄₈N₁₀O₁₅) written on the certificate, not just the name. A vendor who publishes the sequence has committed to a molecule; a vendor who publishes only the product name has committed to a word.
• CAS 62568-57-4 on the label, and regulatory claims that name emideltide. A CAS matching nothing, or none given, indicates a listing assembled from other listings; a page citing "FDA review" without naming emideltide has not read the file it is citing.
• A listing that publishes neither the sequence WAGGDASGE nor a mass result is unverified rather than merely undocumented.